INDIANAPOLIS, Aug. 17 /PRNewswire/ -- Nursing mothers can be tested with Roche Diagnostics’ AmpliChip CYP450 Test to help their doctors determine whether they are ultra-rapid metabolizers of codeine.
The Food & Drug Administration issued a Public Health Advisory on Friday warning nursing mothers about the potential negative effects of codeine while nursing. The advisory is posted at http://www.fda.gov/cder/drug/advisory/codeine.htm.
Roche Diagnostics is the only company that makes an FDA-cleared test for determining a patients’ CYP2D6 genotype, which helps a doctor predict how patients will metabolize certain drugs, including codeine.
The AmpliChip test analyzes variations in two genes -- CYP2D6 and CYP2C19 -- that play a primary role in the metabolism of some drugs used to treat severe depression, schizophrenia, bi-polar disorder, cardiovascular disease treated with beta-blockers, attention deficit/hyperactivity disorder (ADHD) and others.
Knowledge of these gene variations can be used to help individualize drug treatment through selection of the more appropriate drugs and adjustment of dosages. These measures have the potential to improve patient outcome by reducing adverse drug reactions and improving drug efficacy.
For a list of laboratories offering AmpliChip CYP450 Test, go to http://amplichip.us.
About Roche and the Roche Diagnostics Division
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As a supplier of innovative products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is a world leader in diagnostics, the leading supplier of drugs for cancer and transplantation and a market leader in virology. In 2006, sales by the Pharmaceuticals Division totaled 33.3 billion Swiss francs, and the Diagnostics Division posted sales of 8.7 billion Swiss francs. Roche employs roughly 75,000 people in 150 countries and has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai. Roche’s Diagnostics Division offers a uniquely broad product portfolio and supplies a wide array of innovative testing products and services to researchers, physicians, patients, hospitals and laboratories world-wide. For further information, please visit our U.S. website at www.roche-diagnostics.us.
All trademarks used or mentioned in this release are legally protected by law.
For further information please contact: Lori McLaughlin Corporate Communication Roche Diagnostics Corporation, Indianapolis, Ind. Phone: 317-521-3112 lori.mclaughlin@roche.com
Roche Diagnostics
CONTACT: Lori McLaughlin, Corporate Communication of Roche DiagnosticsCorporation, +1-317-521-3112, lori.mclaughlin@roche.com
